• Durability of device [ Time Frame: End of study ]
• Safety assessment via adverse events and clinical measurements [ Time Frame: 2 weekly ]

The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of seasonal allergic rhinitis (SAR).

• Drug: budesonide
  Current product
  Other Name: Rhinocort AQUA
• Device: Budesonide
  New type device
  Other Name: Rhinocort Aqua
• Drug: Placebo

• 1: Experimental
  Rhinocort
  Interventions:

  • Drug: budesonide
  • Device: Budesonide
• 2: Placebo Comparator
  Intervention: Drug: Placebo

Inclusion Criteria:

• In the opinion of the investigator, is a candidate for treatment with nasal steroids based on a history of either a) inadequate control of symptoms with antihistamines, decongestants and/or immunotherapy, or b) prior successful treatment with nasal steroids.
• A documented history of at least one year of seasonal allergic rhinitis.
• A positive response to a skin prick test for grass allergens that must be present in the subject's environment throughout the study.

Exclusion Criteria:

• Primary or secondary adrenal insufficiency
• Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection or structural abnormalities of the nose (e.g., septal deviation, nasal polyps) symptomatic enough to cause significant nasal obstruction as judged by the investigator.
• A diagnosis of asthma requiring treatment as specified in the protocol.